![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
1. Fg-4592
2. Fg4592
1. Fg-4592
2. 808118-40-3
3. Fg4592
4. Roxadustat (fg-4592)
5. Asp1517
6. N-[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine
7. Asp 1517
8. 2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic Acid
9. Glycine, N-[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]-
10. Asp-1517
11. X3o30d9ymx
12. Fg-4592 (asp1517)
13. Chembl2338329
14. Fg 4592
15. (4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)glycine
16. (((4-hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl)amino)acetic Acid
17. Evrenzo
18. 2-(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carboxamido)acetic Acid
19. N-((4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl)glycine
20. N-[(4-hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl]glycine
21. 2-[(1-methyl-4-oxidanyl-7-phenoxy-isoquinolin-3-yl)carbonylamino]ethanoic Acid
22. Roxadustat [usan:inn]
23. Unii-x3o30d9ymx
24. Roxadustatum
25. N-((4-hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl)glycine
26. Glycine, N-((4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl)-
27. 8ho
28. Evrenzo (tn)
29. Fg-4592[roxadustat]
30. Roxadustat [inn]
31. Roxadustat [jan]
32. Roxadustat [usan]
33. Roxadustat(fg-4592)
34. Roxadustat [who-dd]
35. Mls006010023
36. Roxadustat (jan/usan/inn)
37. Schembl523705
38. Gtpl8454
39. Dtxsid60230644
40. Ex-a390
41. Chebi:132774
42. Bcpp000230
43. Hms3654m03
44. Amy16514
45. Bcp02523
46. Bdbm50431015
47. Fg-4592,asp1517
48. Mfcd20040519
49. S1007
50. Zinc71257465
51. Akos026674331
52. Bcp9000684
53. Ccg-268052
54. Cs-1094
55. Db04847
56. Sb16615
57. Ncgc00346527-01
58. Ncgc00346527-07
59. Ac-31003
60. As-17052
61. Hy-13426
62. Smr004701207
63. Db-075703
64. Sw219900-1
65. D10593
66. J-522733
67. Q27088611
68. 2-[[4-hydroxy-1-methyl-7-(phenoxy)isoquinoline-3-carbonyl]amino]acetic Acid
Molecular Weight | 352.3 g/mol |
---|---|
Molecular Formula | C19H16N2O5 |
XLogP3 | 3.4 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 5 |
Exact Mass | 352.10592162 g/mol |
Monoisotopic Mass | 352.10592162 g/mol |
Topological Polar Surface Area | 109 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 508 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
In clinical development for the treatment of anemia of chronic inflammatory disease.
Evrenzo is indicated for treatment of adult patients with symptomatic anaemia associated with chronic kidney disease (CKD).
FG-4592 represents one of several next generation PHI that has been optimized for multiple pharmacokinetic and pharmacodynamic parameters related to erythropoiesis, including selective inhibition of HIF prolyl and asparaginyl hydroxylases, potency, iron utilization, and ADME. FG-4592 represents one of several next generation HIF-PH inhibitors designed to selectively induce the expression of genes that mediate erythropoiesis for the treatment of anemia.
B03XA05
B - Blood and blood forming organs
B03 - Antianemic preparations
B03X - Other antianemic preparations
B03XA - Other antianemic preparations
B03XA05 - Roxadustat
Absorption
Orally active
FG-4592 is an orally active second generation HIF-PH inhibitor. Preclinical studies show that FG-4592 increases production of endogenous erythropoietin (EPO), increases iron mobilization and utilization, and overcomes the suppressive effects of inflammation on red blood cell production.